A vaccine against HI V able to generate properly neutralizing antibodies and an efficacious cytotoxic T-lymphocyte response is of paramount importance. We are proposing a novel approach based on the collection of thousand small HI V-infected human plasma samples for preparing a global vaccine, able to counteract HI V diversity and mutagenicity. The pooled plasmas will undergo several steps for sterilizing and inactivating HI V, possibly other contaminant viruses and other pathogens. The critical step is the prolonged and controlled exposure of plasmas to ozone so that finally each ml of plasma has interacted with a precise dose of ozone. To inactivated plasma, both therapeutic human albumin and ozonated ethyl oleate are added for enhancing a proficient absorption and reaction with the immune system of the vaccine. The need of a partner collaboration for developing the production and the preliminary testing of the vaccine is essential.
Bocci, V., Zanardi, I., Travagli, V. (2010). Ozonation of human HIV-infected plasmas for producing a global vaccine. VIRULENCE, 1(3), 215-217 [10.4161/viru.1.3.11830].
Ozonation of human HIV-infected plasmas for producing a global vaccine
Bocci, Velio;Zanardi, Iacopo;Travagli, Valter
2010-01-01
Abstract
A vaccine against HI V able to generate properly neutralizing antibodies and an efficacious cytotoxic T-lymphocyte response is of paramount importance. We are proposing a novel approach based on the collection of thousand small HI V-infected human plasma samples for preparing a global vaccine, able to counteract HI V diversity and mutagenicity. The pooled plasmas will undergo several steps for sterilizing and inactivating HI V, possibly other contaminant viruses and other pathogens. The critical step is the prolonged and controlled exposure of plasmas to ozone so that finally each ml of plasma has interacted with a precise dose of ozone. To inactivated plasma, both therapeutic human albumin and ozonated ethyl oleate are added for enhancing a proficient absorption and reaction with the immune system of the vaccine. The need of a partner collaboration for developing the production and the preliminary testing of the vaccine is essential.File | Dimensione | Formato | |
---|---|---|---|
BocciVIRU1-3.pdf
accesso aperto
Tipologia:
Post-print
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
145.73 kB
Formato
Adobe PDF
|
145.73 kB | Adobe PDF | Visualizza/Apri |
Virulence2010.pdf
accesso aperto
Tipologia:
PDF editoriale
Licenza:
Creative commons
Dimensione
359.94 kB
Formato
Adobe PDF
|
359.94 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/8300
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo